Laurent MORTIER
University Hospital, Lille · Hôpital Claude-Huriez · Centre Hospitalier Régional et Universitaire de LILLE
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Laurent MORTIER as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05561634 · Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell CarcinomaUniversity Hospital, Lille · recruiting · Basal Cell Carcinoma, Radiotherapy; Complications · principal investigator
- N/ANCT03713203 · PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).University Hospital, Lille · recruiting · Paget Disease of the Vulva, Paget Disease, Extramammary · principal investigator
- N/ANCT03210935 · French National Database of Rare Dermatological CancersUniversity Hospital, Lille · recruiting · Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment · principal investigator
- N/ANCT03076918 · Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic TherapyUniversity Hospital, Lille · completed · Keratosis, Actinic · principal investigator
- N/ANCT03076892 · Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOSUniversity Hospital, Lille · completed · Keratosis, Actinic · principal investigator
- Ph2NCT02667574 · Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)University Hospital, Lille · completed · Basal Cell Carcinoma · principal investigator
- Ph2NCT02662725 · Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain MetastasesUniversity Hospital, Lille · completed · Melanoma, Brain Metastasis · principal investigator
- Ph1NCT01469455 · DNA Repair Inhibitor & Irradiation on MelanomaDNA Therapeutics · completed · Local Metastatic Melanoma · principal investigator
- Ph2NCT00910676 · Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor InhibitorsCentre Oscar Lambret · completed · Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:47 UTC. The ranking covers the 200 most relevant of 59 PubMed records, and a shared surname and initials can bring in a namesake. All 59 on PubMed
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med · 20154,791 citationsRCR 149.2
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med · 20154,573 citationsRCR 142.4
- 2,142 citationsRCR 66.8
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.N Engl J Med · 20171,200 citationsRCR 38.6
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.N Engl J Med · 20161,066 citationsRCR 32.4
- 984 citationsRCR 29.7
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol · 2019952 citationsRCR 33.1
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.Lancet Oncol · 2012734 citationsRCR 19.2
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Lancet Oncol · 2017611 citationsRCR 19.2